cloud_upload Publier
search
eisai-europe-limited

eisai-europe-limited

Publications

expand_more
Eisai Disagrees with German Institute for Quality and Efficiency in Health Care (IQWiG) Report on Innovative Antiepileptic Drug Fycompa® (Perampanel) for the Treatment of Partial Epilepsy -
Eisai Disagrees with German Institute for Quality and Efficiency in Health Care (IQWiG) Report on Innovative Antiepileptic Drug Fycompa® (Perampanel) for the Treatment of Partial Epilepsy
3 pages
Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological Diseases -
Eisai and UCL Form Major Drug Discovery Alliance to Develop New Therapeutics for Neurological Diseases
2 pages
Scottish Medicines Consortium Approves Fycompa® (Perampanel) - Once Daily Anti-Epileptic Treatment -
Scottish Medicines Consortium Approves Fycompa® (Perampanel) - Once Daily Anti-Epileptic Treatment
3 pages
Results Announced for Phase III Head-to-head Study of Halaven® (eribulin) Versus Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer -
Results Announced for Phase III Head-to-head Study of Halaven® (eribulin) Versus Capecitabine (Xeloda®) in Patients With Locally Advanced or Metastatic Breast Cancer
3 pages
Eisai to Present New Research on Halaven (Eribulin) at 35th Annual San Antonio Breast Cancer Symposium -
Eisai to Present New Research on Halaven (Eribulin) at 35th Annual San Antonio Breast Cancer Symposium
2 pages
All Wales Strategic Medical Group Approves Zebinix® (Eslicarbazepine Acetate) - Once Daily Anti-Epileptic Treatment -
All Wales Strategic Medical Group Approves Zebinix® (Eslicarbazepine Acetate) - Once Daily Anti-Epileptic Treatment
3 pages
All Wales Strategic Medical Group and Scottish Medicines Consortium Accept use of Inovelon® (rufinamide) Drinkable, Child-friendly Formulation -
All Wales Strategic Medical Group and Scottish Medicines Consortium Accept use of Inovelon® (rufinamide) Drinkable, Child-friendly Formulation
3 pages
Eisai
Eisai's Halaven First Breast Cancer Therapy for Which Price Negotiations with the National Association of Statutory Health Insurance Funds were Successfully Concluded
3 pages
First Presentation of Pooled Phase III Data Supporting Europe
First Presentation of Pooled Phase III Data Supporting Europe's Newest Partial Epilepsy Treatment
3 pages
New Studies on Zebinix® Presented at Leading European Epilepsy Congress -
New Studies on Zebinix® Presented at Leading European Epilepsy Congress
7 pages
New Research on Eisai
New Research on Eisai's Antiepileptic Drug Zonegran®(Zonisamide) Presented at European Congress on Epileptology (ECE)
4 pages
Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology -
Eisai Presents new Research for Investigational Compound Lenvatinib at the European Society for Medical Oncology
3 pages
Japanese Pharmaceutical Company Announces Transfer of Global Manufacturing for New Epilepsy Medicine to the UK -
Japanese Pharmaceutical Company Announces Transfer of Global Manufacturing for New Epilepsy Medicine to the UK
4 pages
New First-in-Class Treatment Fycompa® Launches in Denmark for Most Common Form of Epilpesy -
New First-in-Class Treatment Fycompa® Launches in Denmark for Most Common Form of Epilpesy
5 pages
Hoy se comercializa Fycompa®, el primer tratamiento de su clase, para las personas con la forma más frecuente de epilepsia -
Hoy se comercializa Fycompa®, el primer tratamiento de su clase, para las personas con la forma más frecuente de epilepsia
5 pages
Fycompa®, premier médicament antiépileptique de nouvelle génération, est mis aujourd
Fycompa®, premier médicament antiépileptique de nouvelle génération, est mis aujourd'hui à disposition des patients souffrant de la forme la plus courante de l'épilepsie
5 pages
New First-In-Class Treatment Fycompa® Launches Today for People With the Most Common Form of Epilepsy -
New First-In-Class Treatment Fycompa® Launches Today for People With the Most Common Form of Epilepsy
5 pages
New First-In-Class Treatment Fycompa® [black triangle drug] Launches Today for Most Common Form of Epilepsy -
New First-In-Class Treatment Fycompa® [black triangle drug] Launches Today for Most Common Form of Epilepsy
3 pages
Se presentan los resultados del último estudio pivotal de fase III de Fycompa® (perampanel) antes de su comercialización en Europa -
Se presentan los resultados del último estudio pivotal de fase III de Fycompa® (perampanel) antes de su comercialización en Europa
7 pages
Publication des resultats du dernier essai pivot de phase III mene sur Fycompa ® (perampanel) juste avant sa premiere mise a disposition sur le marche en Europe -
Publication des resultats du dernier essai pivot de phase III mene sur Fycompa ® (perampanel) juste avant sa premiere mise a disposition sur le marche en Europe
7 pages
Final Pivotal Phase III Fycompa® (perampanel) Study Results Published Ahead of First European Launch -
Final Pivotal Phase III Fycompa® (perampanel) Study Results Published Ahead of First European Launch
6 pages
La Comisión Europea aprueba Fycompa® (perampanel) de Eisai la primera aprobación en el mundo para una nueva clase de tratamiento contra la epilepsia -
La Comisión Europea aprueba Fycompa® (perampanel) de Eisai la primera aprobación en el mundo para una nueva clase de tratamiento contra la epilepsia
5 pages
Se publica en Neurology® un estudio fundamental de Fycompa® (perampanel), tratamiento de Eisai para la epilepsia parcial -
Se publica en Neurology® un estudio fundamental de Fycompa® (perampanel), tratamiento de Eisai para la epilepsia parcial
5 pages
Eisai obtient l
Eisai obtient l'autorisation de mise sur le marché pour Fycompa® (pérampanel)
6 pages
expand_more

Youscribe

Le catalogue

Le service

Les conditions

facebook twitter instagram youtube
playstore
appstore
© 2010-2019 YouScribe
Rapport de stage conclusion Poésie en prose Livre en ligne Tout le catalogue Toute la communauté